Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | MTOR | P42345 | 2/20 | 0.39 |
| ▸ | PDE2A | O00408 | 4/20 | 0.37 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | CPS1 | P31327 | 1/20 | 0.33 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.33 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22628284 | 0.85 | TRPM8 (0.36) | PIK3CAMTORPDE2AGPR119TRPM8 | |
| SCHEMBL1194900 | 0.84 | KDM4E (0.36) | PIK3CAMTORPDE2AMLYCDCLK1 | |
| SCHEMBL6710893 | 0.81 | CES2 (0.53) | PIK3CAMTORMLYCDTRPM8CPS1 | |
| SCHEMBL23003420 | 0.80 | PDK2 (0.42) | PIK3CAMTORMLYCDGPR119TRPM8 | |
| SCHEMBL29688875 | 0.80 | PIK3CA (0.43) | PIK3CAMTORMLYCDGPR119CLK1 | |
| SCHEMBL20982579 | 0.80 | MLYCD (0.49) | PIK3CAMTORMLYCDGPR119CLK1 | |
| SCHEMBL12121067 | 0.80 | PIK3CA (0.43) | PIK3CAMTORMLYCDGPR119CLK1 | |
| SCHEMBL30514003 | 0.78 | CPS1 (0.55) | CLK1DYRK1ADYRK1BCPS1KMT2A | |
| SCHEMBL24452660 | 0.78 | PIK3CA (0.40) | PIK3CAMTORMLYCDGPR119CLK1 | |
| SCHEMBL2645212 | 0.78 | PIK3CA (0.45) | PIK3CAMTORMLYCDGPR119CLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4272836-A2 | CD73 INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| US-20220162253-A1 | CD73 INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2022-05-26 | — | — | US | disclosed |
| WO-2020221209-A1 | CD73 INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海和誉生物医药科技有限公司 | 2020-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162253-A1 | CD73 INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ENTPD5, ENTPD1, NT5E | PIK3CA 182/4885MTOR 1969/4885PDE2A 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.